This week, we talk about the upcoming Lund Spring Symposium with Claes Wahlestedt, Leonard M. Miller professor and director of the Center for Therapeutic Innovation (CTI) and associate dean for therapeutic innovation at the University of Miami Miller School of Medicine; about Meet2Win with Lucia Robert, CEO of MATWIN who organized the event; and then interviews with two people, Andrew Clutterbuck, MSAT EMEA associate director and Mark Peacock, associate director, technical applications, from Merck.
This week’s podcast is sponsored by Merck.
Merck is a science and technology company, operating across life sciences, healthcare and electronics. The company provides products and services that accelerate the development and manufacture of drugs and finds ways to treat the most challenging diseases to enable device intelligence.
Merck holds the global rights to the Merck name and brand. The only exceptions are the US and Canada, where Merck’s business sector operates as MilliporeSigma in life sciences.
Lund Spring Symposium
The new event, which will include presentations by Nobel laureates, will showcase the best of pharmacology.
The Lund Spring Symposium, which runs from 24 to 26 May at Palaestra et Odeum in Lund, Sweden, aims to raise the profile of pharmacology as a cross-functional discipline in the 21st century and provide a forum to facilitate collaboration across academics. and industry.
The 8th annual MEET2WIN event is taking place in Bordeaux, France, from May 11 to 12.
The MEET2WIN convention, staged by MATWIN (Maturation & Accelerating Translation With Industry) brings together nearly 300 European players specifically engaged in translation research and innovation in oncology (researchers, doctors, entrepreneurs, biotech, pharmaceutical groups, investors, support structures, etc. ) wanted to expand their network of contacts and optimize their collaboration around the fight against cancer.
More than 1,000 companies and organizations attended the event, with more than 5,000 meetings scheduled.